Medications for Alcohol Use Disorder: Options and Questions

Which medications are approved for alcohol use disorder?

Naltrexone, acamprosate, and disulfiram are approved in the United States for alcohol use disorder. Medication can be used with behavioral treatment, including individual therapy, and does not require a person to choose between medical care and counseling. The three options differ in treatment goal, basic action, formulation, timing, and medical considerations.

No medication is best for everyone. Prescribing decisions account for treatment goals, current or anticipated opioid use, physical health, pregnancy, other medicines, preferences, and follow-up needs.

How is naltrexone used in alcohol treatment?

Naltrexone acts on opioid receptors and reduces craving or heavy drinking for some people. It is available as a daily tablet and a monthly extended-release injection, and the two have different starting instructions: oral naltrexone may be started during ongoing drinking after a prescribing assessment, while the injection's alcohol-dependence labeling says the person should not be actively drinking at the first dose, even though some clinical guidance allows starting it despite continued alcohol use. The prescriber decides which applies.

Ask how medication appointments will continue after a residential stay or travel.

Naltrexone is available as a daily tablet or a monthly injection. Starting requirements differ by formulation; a prescriber needs to review alcohol use, opioid exposure, pain treatment, and other health factors. Naltrexone can precipitate withdrawal in someone dependent on opioids and blocks opioid effects, so tell treating clinicians about it before procedures or pain care. Ask which formulation fits and how treatment will be monitored.

How does disulfiram differ from craving-focused medications?

Disulfiram interferes with alcohol metabolism and can cause an unpleasant reaction when alcohol is consumed. Its purpose is to support abstinence through an alcohol-deterrent effect rather than directly reduce craving. It requires informed participation and careful attention to alcohol exposure, medical history, other medications, and follow-up.

The prescriber explains disulfiram safety and whether supervised administration fits the plan. The program identifies prescribing responsibility, the response to adverse effects, and how behavioral care accompanies medication.

How do naltrexone, acamprosate, and disulfiram compare?

These are the questions a prescriber works through with you, not a self-assessment. Is the goal to cut down or to stop completely? Naltrexone can help reduce heavy drinking; acamprosate supports continued abstinence after stopping. Are opioids involved, now or foreseeably, including for pain treatment? Naltrexone can block opioid pain relief and precipitate withdrawal in someone dependent on opioids, so the prescriber needs to review this before considering it. Acamprosate may be an alternative if kidney function allows. Would a medication that deters drinking fit the person's goals and daily routine? Disulfiram requires an understanding of the potentially serious alcohol reaction and a workable dosing plan. Acamprosate needs dose adjustment with moderately reduced kidney function and must not be used with severe kidney impairment; disulfiram requires review of heart and liver conditions. Generic tablets may cost less than injectable formulations, but coverage and pharmacy prices vary. NIAAA's overview of alcohol use disorder medications explains each in more depth.

Swipe sideways to see all columns.

Can alcohol use disorder medication be used during rehab?

Yes, when clinically appropriate. Alcohol medication and individual behavioral care address different treatment needs in residential or outpatient settings; the arrangement requires an appropriate prescriber, access to the medicine, and follow-up.

Before admission, confirm who prescribes, whether the program accepts all evidence-based medications, how laboratory or medical follow-up is handled, how medication continues during travel or transitions, and whether medication decisions are protected from nonmedical program rules.

The written schedule includes the next review date and the provider responsible for receiving the medication history after discharge.

Starting can be considered during or immediately after withdrawal management, when the person is stable, monitored, and about to face the first weeks at risk; timing depends on the medication, formulation, withdrawal status, and clinical assessment. Some residential programs still do not offer it, or offer only one option, on the theory that recovery should be medication-free; that view is not supported by the evidence and is a reason to ask about it in the first call. A program that supports all three, has a prescriber on its team or on call, and names who continues the prescription after discharge is doing this properly.

Why are medications for alcohol use disorder sometimes overlooked?

Many people assume alcohol treatment must rely only on counseling, mutual-support meetings, or willpower. Others hear the word medication and expect sedation, intoxication, or a replacement substance. The three approved AUD medications are nonaddictive and are used to support change without producing an alcohol-like effect.

Medication is also overlooked when a program has no prescriber, staff are unfamiliar with the options, or treatment is organized around one fixed philosophy. A neutral program should explain options and limitations without pressuring a person toward or away from medication.

What should you ask a prescribing clinician about AUD medication?

The prescribing conversation covers treatment goals, current drinking, other substances and medicines, medical conditions, expected effects, precautions, and follow-up. The decision is individual rather than a universal ranking of medications.

What treatment goal is this medication intended to support?

Clarify reduced heavy drinking, abstinence maintenance, alcohol deterrence, or another defined goal.

What parts of my health and medication history matter?

Discuss current medicines, opioid use, pain care, liver and kidney health, pregnancy, and other relevant conditions.

What benefits and side effects should I understand?

Ask what to expect, what needs monitoring, and whom to contact with a concern.

How will medication fit with counseling?

Define behavioral care, individual sessions, family involvement, recovery support, and follow-up.

How will access continue if my setting changes?

Confirm prescribing, pharmacy, injection appointments if relevant, travel, and discharge planning.

How private care delivers the treatment

Private medication care consists of prescribing appointments, a pharmacy or administration arrangement, and follow-up monitoring. The clinician and patient review response and unwanted effects. The accommodation provider does not make prescribing decisions unless an appropriately qualified professional holds that responsibility.

For example, a person in a private residence might see an outside prescriber while receiving individual therapy on site. The appointment, transport, medication supply, and next review need to be coordinated. Before the residence booking ends, the receiving clinician needs the current list and the treatment response recorded so follow-up starts with an accurate history.

For someone avoiding insurance records, private delivery means a physician or nurse practitioner who bills directly, a pharmacy that fills without a claim, and, for the monthly naltrexone injection, a practice that stocks it. Concierge and private addiction medicine practices do all three. The costs are the visits and the drug, and the drug is the smaller part except for the injection.

What to clarify about alcohol treatment medications

The treatment calendar identifies the prescribing appointment and follow-up alongside behavioral sessions. That arrangement gives the patient a clear next date and a named provider.

A medication is discussed without a clinical evaluation

Before starting naltrexone, the prescriber needs to assess recent opioid use and whether testing is needed to avoid precipitated withdrawal. Acamprosate requires a kidney-function assessment; disulfiram requires review of liver function, heart conditions, medicines, and alcohol exposure. Discussing an option is different from deciding it is safe to prescribe.

Follow-up responsibility is unclear

Someone has to review side effects, decide on the prescriber's schedule whether to adjust or switch if drinking has not changed, and renew the prescription for months. Name that person before the first dose.

Medication and other support are disconnected

Medication reduces craving and heavy drinking; it does not teach anyone what to do on a Friday evening. The plan pairs it with therapy and a continuing-care schedule, and the prescriber and therapist share progress with the person's consent.

Monitoring alcohol medication over time

Medication follow-up reviews the treatment goal, response, adverse effects, and practical access. Prescribers also consider changes in other medications and physical health. A stay ending or an insurance change needs an access plan, not an unplanned interruption.

Naltrexone, acamprosate, and disulfiram are not interchangeable. A response to one medicine, or a reason it is unsuitable, does not answer whether another option fits.

A record of the treatment goal and response helps the next clinician continue the discussion without starting from an incomplete history.

Common questions about medications for alcohol use disorder

Sources and further reading

• NIAAA: Evidence-Based Alcohol Treatment Options
• NIAAA: Understanding Alcohol Use Disorder
• NIAAA: Finding and Getting Help
• SAMHSA: Substance Use Disorder Treatment Options
• NIDA: Principles of Drug Addiction Treatment, Third Edition
• ASAM: Alcohol Withdrawal Management Guideline
• FDA labeling via DailyMed: Vivitrol (naltrexone)
• FDA labeling via DailyMed: Acamprosate
• FDA labeling via DailyMed: Disulfiram
• SAMHSA TIP 49: Oral Naltrexone
• NYSDOH AI and Johns Hopkins: Treatment of Alcohol Use Disorder

Sources checked September 7, 2026